Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Juan Esteban Gómez‐Mesa et al.|New England Journal of Medicine|2021Cited by 4.6k
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection FractionMilton Packer, Faı̈ez Zannad, Stefan D. Anker et al.|Circulation|2020Cited by 422
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes StatusStefan D. Anker, Milton Packer, Javed Butler et al.|Circulation|2020Cited by 350
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faı̈ez Zannad et al.|Circulation|2021Cited by 343
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135